About Imperagen
Imperagen is a Healthcare company based in Manchester (United Kingdom) founded in 2021 by Timothy Eyes, Andrew Almond, and Andrew Currin. An enzyme engineering platform is developed for drug development applications. Imperagen has raised $10.99 million across 2 funding rounds from investors including Northern Gritstone, IQ Capital and PXN Ventures. Its chief executive, as recorded, is Andrew Almond. Imperagen offers products and services including Digital Enzyme Evolution Platform and AI-powered Hotspot Identification. Its focus areas include Life Sciences, Life Sciences Platforms and Tools, Research Assays and Drug Discovery.
Company details
Imperagen was founded in 2021 in Manchester, United Kingdom, within the biotechnology sector. An enzyme engineering platform is utilized by the company to advance drug development processes. Enzyme products are provided for manufacturing complex drug molecules. Operations extend to laboratory tools, enzyme replacement therapies, and drug delivery systems, supporting various pharmaceutical applications in the region.
- Headquarters Manchester, United Kingdom
- Founders Timothy Eyes, Andrew Almond, Andrew Currin
- SectorsHealthcare
- Website imperagen.com
- Social LinkedIn X
- Legal Name Imperagen
- Total Equity Funding$10.99M (USD)
in 2 rounds
- Latest Funding Round$6.71M (USD), Seed
May 2026
- InvestorsNorthern Gritstone
& 2 more
Products & Services of Imperagen
Imperagen offers a comprehensive portfolio of products and services, including Digital Enzyme Evolution Platform and AI-powered Hotspot Identification.
AI and automation platform accelerates enzyme development for performance improvements.
Identifies key enzyme parts using algorithms for faster experimental predictions.
Funding Insights of Imperagen
Imperagen has successfully raised a total of $10.99M across 2 strategic funding rounds. The most recent funding activity was a Seed round of $6.71 million completed in May 2026. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $10.99M
- Total Rounds 2
- Last Round Seed — $6.71M
- First Round $4.28M
(Aug 2022)
- Investors Count 3
All 2 funding rounds of Imperagen with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| May 2026 | $6.71M | Seed | – | PXN Ventures | |
| Aug 2022 | $4.28M | Seed | – | Northern Gritstone, IQ Capital | – |
3 investors in total: 3 institutional.
Investors in Imperagen
Imperagen has secured backing from 3 investors, including venture fund investors. Prominent investors backing the company include Northern Gritstone, IQ Capital and PXN Ventures.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Investment firm focused on investing in science and technology firms | 2020 | northern-gritstone.com | Manchester, United Kingdom | |
Deep tech venture capital firm investing in European and global startups. | iqcapital.vc | |||
| pxnventures.co.uk |
Investor details for Imperagen
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Imperagen
3 people are tracked at Imperagen (3 in leadership).
| Name | Role | Group |
|---|---|---|
Timothy Eyes | Co-Founder | Leadership |
Andrew Almond | Co-Founder & CEO | Leadership |
Andrew Currin | Co-Founder | Leadership |
Complete people profiles for Imperagen
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Timeline of Imperagen
3 dated milestones of Imperagen across 5 years, from founding to its latest funding, stage changes and deals.
- Founded Imperagen is founded.
- Funding First funding round of $4.3M.
- Funding Latest funding round, Seed, of $6.7M.
Top companies in Life Sciences Platforms & Tools
3 companies that operate in the same segment as Imperagen (Life Sciences Platforms & Tools) in United Kingdom, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Nanopore-based electronic systems for single-molecule analysis are developed. | 2005 | Oxford, Oxfordshire, United Kingdom | USD 1.34 B | USD 301.49 M | 1,372 | |
Genetically modified cell lines are developed using AAV gene-editing platform. | 2007 | Cambridge, Cambridgeshire, United Kingdom | USD 46.29 M | |||
Biological reagents and antibodies are developed for life science research. | 1998 | Cambridge, Cambridgeshire, United Kingdom | USD 78.8 M |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Imperagen
Complete news archive for Imperagen
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Imperagen
Imperagen was founded in 2021 and raised its 1st funding round 1 year after it was founded.
Imperagen is headquartered in Manchester, United Kingdom. It is registered at Manchester, Greater Manchester, United Kingdom.
Andrew Almond is the CEO of Imperagen, as recorded in our data. They have also founded this company.
Imperagen is a funded company, having raised a total of $10.99M across 2 funding rounds to date. The company's 1st funding round was a Seed of $4.28M, raised on Aug 2022.
Imperagen was founded in 2021 in Manchester, United Kingdom, within the biotechnology sector. An enzyme engineering platform is utilized by the company to advance drug development processes. Enzyme products are provided for manufacturing complex drug molecules. Operations extend to laboratory tools, enzyme replacement therapies, and drug delivery systems, supporting various pharmaceutical applications in the region.
Imperagen offers Digital Enzyme Evolution Platform and AI-powered Hotspot Identification.
Imperagen has 3 investors. Key investors include Northern Gritstone, IQ Capital, and PXN Ventures.
Imperagen operates through Imperagen.